Launch Quantities for Nucynta IR Authorized Generic Sample Clauses

Launch Quantities for Nucynta IR Authorized Generic. (i) The Parties’ intent is for Hikma to launch the Nucynta IR Authorized Generic in the Territory no later than the market entry of a Generic Equivalent of such Product by a Third Party in the Territory. Accordingly, and, provided that Collegium obtains DEA quota as necessary under Applicable Law to Manufacture and supply Hikma with Hikma’s forecasted supply quantities of the Nucynta IR Authorized Generic in accordance with the terms of the Manufacturing Agreement, Collegium shall have a certain initial volume of the Nucynta IR Authorized Generic Manufactured and Labeled for Hikma no later than (such date, the “Launch Delivery Date”): [***]. ​ (ii) Hikma may waive Collegium’s obligations under clause (i) above if [***]. Notwithstanding any of the provisions in this Section 1.3(d)(ii) to the contrary, if Collegium’s obligations have been timely waived, and [***], then Collegium will use Commercially Reasonable Efforts to provide Launch Quantities on, or as soon as possible after, the Launch Delivery Date. (iii) Xxxxx will pay Collegium the Transfer Price for all of the “initial volume” of Nucynta IR Authorized Generic manufactured and labeled for Hikma pursuant Section 1.3(d)(i) above regardless of whether or when market entry of a Generic Equivalent by a Third Party occurs, the details of the corresponding invoicing and payment to be set forth in the Manufacturing Agreement. Any and all such “initial volume” of Nucynta IR Authorized Generic manufactured and labeled for Hikma pursuant Section 1.3(d)(i) will not be deemed Obsolete and Slow Moving Items regardless of the remaining shelf life for such inventory of Product at the time of Xxxxx’s First Commercial Sale of such Product. [***].